Spago Nanomedical recently submitted the application to start the phase I/IIa study with Tumorad in Australia. Spago’s Chief Development Officer Paul Hargreaves visited BioStock’s studio to talk about the new radionuclide therapy and the upcoming study.
Watch the interview with Spago Nanomedical’s CDO Paul Hargreaves in the link below.
Learn more about Spago Nanomedical on the company’s website.The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.